AGA Medical Pursues Stroke, Migraine Indications And $200 Mil. IPO
This article was originally published in The Gray Sheet
Executive Summary
AGA Medical hopes to complete a pivotal U.S. trial by year-end assessing its Amplatzer PFO Occluder for prevention of recurrent cryptogenic strokes, the company says in a June 20 prospectus for a planned initial public offering worth up to $200 million
You may also be interested in...
Will Positive PFO Closure Trials For Stroke Help Or Hurt Other Indications?
As pivotal trials for patent foramen ovale (PFO) closure devices to treat stroke start wrapping up, cardiologists are questioning what impact the trial results will have on studies for other indications
Will Positive PFO Closure Trials For Stroke Help Or Hurt Other Indications?
As pivotal trials for patent foramen ovale (PFO) closure devices to treat stroke start wrapping up, cardiologists are questioning what impact the trial results will have on studies for other indications
People In Brief
AGA Medical CEO and IPO: Structural heart defect devices firm names a new CEO June 20 and on the same day files with the U.S. Securities and Exchange Commission for an initial public stock offering to raise up to $200 million. Chief Operating Officer John Barr is appointed president and CEO to replace Frank Gougeon, who co-founded the company with Kurt Amplatz in 1995. AGA says that Gougeon has decided to transition from day-to-day company oversight to an expanded role in long-term strategic planning. He will remain a member of the company's board and will chair a new corporate development committee